Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
Galectin's stock halves after phase 3 MASH trial misses goal
Since the biotech shared the phase 3 data this morning, the company’s stock has dropped 54%, from $2 per share to 92 cents.
Gabrielle Masson
Dec 20, 2024 2:40pm
Apollomics, after giving up on leukemia drug, posts ph. 3 fail
Dec 20, 2024 9:30am
Novo stock crashes after CagriSema misses weight-loss goal
Dec 20, 2024 8:15am
Omeros stock up after data analysis spurs BLA resubmission plan
Dec 19, 2024 10:54am
Regeneron anticoagulant bests enoxaparin, matches Eliquis
Dec 19, 2024 8:50am
Vertex's pain prospect underwhelms versus placebo, sinking stock
Dec 19, 2024 7:41am
